|
Registro Completo |
|
Biblioteca(s): |
Embrapa Instrumentação. |
|
Data corrente: |
08/08/2024 |
|
Data da última atualização: |
28/08/2024 |
|
Tipo da produção científica: |
Artigo em Periódico Indexado |
|
Autoria: |
ISLAM, A.; SILVA, S. R. da; DUARTE, E. C.; TOTARO, P. I. S. de; DITTZ, D.; COLNAGO, L. A.; PAIVA, F. F.; LOPES, M. T. P.; MENDES, E. M. A. M.; RIAZ, F.; FREZARD, F.; DEMICHELI, C. |
|
Afiliação: |
UNIVERSIDADE FEDERAL DE MINAS GERAIS.; UNIVERSIDADE FEDERAL DE MINAS GERAIS; UNIVERSIDADE FEDERAL DE MINAS GERAIS; UNIVERSIDADE FEDERAL DE MINAS GERAIS; FEDERAL UNIVERSITY OF PIAUÍ; LUIZ ALBERTO COLNAGO, CNPDIA; UNIVERSITY OF SAO PAULO; FEDERAL UNIVERSITY OF MINAS GERAIS; UNIVERSIDADE FEDERAL DE MINAS GERAIS; INTERNATIONAL ISLAMIC UNIVERSITY; UNIVERSIDADE FEDERAL DE MINAS GERAIS; UNIVERSIDADE FEDERAL DE MINAS GERAIS. |
|
Título: |
Nanostructured gadolinium(III) micelles: Synthesis, characterization, cytotoxic activities, and MRI applications in vivo. |
|
Ano de publicação: |
2024 |
|
Fonte/Imprenta: |
Nanomedicine: Nanotechnology, Biology, and Medicine, v. 62, 102770, 2024. |
|
Páginas: |
1 - 8 |
|
ISSN: |
1549-9634 |
|
DOI: |
https://doi.org/10.1016/j.nano.2024.102770 |
|
Idioma: |
Inglês |
|
Conteúdo: |
Gadolinium-based contrast agents (GBCAs) are used in around 40 % oJ MRI procedures. Despite initial perceptions oJ minimal risk, their long-term use has emphasized the need to reduce toxicity and develop more eJScient GBCAs with extended blood retention. Advancements in nanomaterials have led to improved GBCAs, enhancing MRI diagnostics. This study synthesizes and characterizes nanostructured gadolinium(III) micelles as superior MRI contrast agents. The complexes, [Gd(L)2], where L is a ligand oJ the N-alkyl-N-methylglucamine surJactant series (L8, L10 or L12, L10), Jorm nanostructured micelles in aqueous solution. Gd(L8)2 and Gd(L10)2 relaxivities remained stable across concentrations. Compared to Gd-DTPA, Gd(III) micelles showed enhanced T1-weighted MRI contrast. Gd(L12)2 micelles exhibited cytotoxicity against B16F10 melanoma cells (IC50 42.5 × 2.2 μM) and L292L929 Sbroblasts (IC50 52.0 × 2.5 μM), with a selectivity index oJ 1.2. In vivo application in mice brain T2-weighted images suggests nanostructured Gd(III) micelles are promising MRI contrast agents Jor targeting healthy organs or tumors. |
|
Palavras-Chave: |
Antitumor activity; Gadolinium(III) nanostructured micelles; Methylglucamine surJactants; N-alkyl-N-methylglucamine surfactants. |
|
Categoria do assunto: |
-- |
|
Marc: |
LEADER 02191naa a2200337 a 4500
001 2166369
005 2024-08-28
008 2024 bl uuuu u00u1 u #d
022 $a1549-9634
024 7 $ahttps://doi.org/10.1016/j.nano.2024.102770$2DOI
100 1 $aISLAM, A.
245 $aNanostructured gadolinium(III) micelles$bSynthesis, characterization, cytotoxic activities, and MRI applications in vivo.$h[electronic resource]
260 $c2024
300 $a1 - 8
520 $aGadolinium-based contrast agents (GBCAs) are used in around 40 % oJ MRI procedures. Despite initial perceptions oJ minimal risk, their long-term use has emphasized the need to reduce toxicity and develop more eJScient GBCAs with extended blood retention. Advancements in nanomaterials have led to improved GBCAs, enhancing MRI diagnostics. This study synthesizes and characterizes nanostructured gadolinium(III) micelles as superior MRI contrast agents. The complexes, [Gd(L)2], where L is a ligand oJ the N-alkyl-N-methylglucamine surJactant series (L8, L10 or L12, L10), Jorm nanostructured micelles in aqueous solution. Gd(L8)2 and Gd(L10)2 relaxivities remained stable across concentrations. Compared to Gd-DTPA, Gd(III) micelles showed enhanced T1-weighted MRI contrast. Gd(L12)2 micelles exhibited cytotoxicity against B16F10 melanoma cells (IC50 42.5 × 2.2 μM) and L292L929 Sbroblasts (IC50 52.0 × 2.5 μM), with a selectivity index oJ 1.2. In vivo application in mice brain T2-weighted images suggests nanostructured Gd(III) micelles are promising MRI contrast agents Jor targeting healthy organs or tumors.
653 $aAntitumor activity
653 $aGadolinium(III) nanostructured micelles
653 $aMethylglucamine surJactants
653 $aN-alkyl-N-methylglucamine surfactants
700 1 $aSILVA, S. R. da
700 1 $aDUARTE, E. C.
700 1 $aTOTARO, P. I. S. de
700 1 $aDITTZ, D.
700 1 $aCOLNAGO, L. A.
700 1 $aPAIVA, F. F.
700 1 $aLOPES, M. T. P.
700 1 $aMENDES, E. M. A. M.
700 1 $aRIAZ, F.
700 1 $aFREZARD, F.
700 1 $aDEMICHELI, C.
773 $tNanomedicine: Nanotechnology, Biology, and Medicine$gv. 62, 102770, 2024.
Download
Esconder MarcMostrar Marc Completo |
|
Registro original: |
Embrapa Instrumentação (CNPDIA) |
|
